Streptomyces Bikiniensia Patents (Class 435/891)
  • Patent number: 6159720
    Abstract: A highly active cellulase suitable for use in a removal of nap of cellulose-containing fibers, a process for reducing cellulose-containing fibers and a process for decoloring denim-dyed cellulose-containing fibers, and its gene are provided. A novel cellulase NCE4 isolated from Humicola insolens is a highly active cellulase, and can be used for various treatments of cellulose-containing fibers.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: December 12, 2000
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Kouichirou Murashima, Tatsuki Moriya, Toru Hamaya, Jinichiro Koga, Naomi Sumida, Kaoru Aoyagi, Takeshi Murakami, Toshiaki Kono
  • Patent number: 5300632
    Abstract: The present invention provides a method for purification of a surface exposed, immunogenic outer membrane protein of Haemophilus influenzas which is conserved amongst strains. The protein, designated P6, is relatively free of detergent, contaminating RNA and undesirable cellular components.In accordance with the present invention, there is provided a method for purifying an immunogenic outer membrane protein of H. influenzas consisting essentially of:a) suspending H.
    Type: Grant
    Filed: December 12, 1991
    Date of Patent: April 5, 1994
    Assignee: Research Foundation of State University of New York
    Inventors: Timothy F. Murphy, Michael A. Apicella
  • Patent number: 5169840
    Abstract: The present invention is directed to a material and method for the stimulation of the production of cytokines. Several polysaccharides, including polymers of different size of .sym.1-4 linked D-mannuronic acid (poly-M and M-blocks), chitosan and cellulose oxidized in C-6 position C60XY) induce human monocytes to produce the cytokines. Preferably, the molecular weights of poly-M and chitosan are above 50,000 and 20,000 respectively. Pretreatment of the monocytes with IFN-.gamma. increases the cytokine production from monocytes stimulated with all polysaccharides tested. The subject polysaccharides worked in vivo and in vitro.The present invention has therapeutic utility as vaccine adjuvants and components. Therapeutic compositions comprising biologically active quantities of the compositions of the present invention may be employed to potentiate antibody production in response to vaccine antigens. Anti-tumor, anti-bacteriological, anti-fungal and anti-viral effects may be expected.
    Type: Grant
    Filed: March 27, 1991
    Date of Patent: December 8, 1992
    Assignees: Nobipols Forskningsstiftelse, Protan Biopolymer A/S
    Inventors: Marit Otterlei, Terje Espevik, Gudmund Skjak-Brock, Olav Smidsrod